Nasdaq FB FaceBook

Below is Validea's ETF fundamental report for Schwab U.S. Dividend Equity ETF (SCHD). The report looks at SCHD's exposure to the major investing factors including value, quality, momentum and low volatility. Schwab U.S. Dividend Equity ETF (SCHD) is a Large-Cap Quality

Below is Validea's ETF fundamental report for SPDR Technology Select Sector SPDR Fund (XLK). The report looks at XLK's exposure to the major investing factors including value, quality, momentum and low volatility. SPDR Technology Select Sector SPDR Fund (XLK) is a Large-Cap

The Houthi's Al-Masira television said on Saturday that the U.S. and the UK launched two airstrikes that targeted the port of Ras Issa, Yemen's main oil export terminal.

Yum! Brands, Inc. YUM recently announced a hike in its quarterly dividend payout. The company raised its quarterly dividend by 11%, which reflects its intention to utilize free cash to boost shareholders’ returns.YUM increased its

MAG Silver Corp. MAG reported that the Juanicipio Project achieved notable results in the fourth quarter of 2023, producing 4.5 million ounces of silver and 10,591 ounces of gold. This brings the total output for 2023 to 16.8 mill

The Kraft Heinz Company KHC is keen on transforming its business to unleash its full potential. The consumer products company is focused on effective pricing strategies to counter inflationary headwinds.Let’s discuss this in detai

Barrick Gold Corporation GOLD recently announced that the Super Pit expansion project at the Lumwana copper mine has been expedited, with initial production now slated for 2028. During a meeting with Zambian President Hakainde Hic

U.S. President Joe Biden's administration on Friday formally informed Congress of its intention to proceed with the $23 billion sale of F-16 fighter jets to Turkey, taking a major step toward completing a long-delayed process that tested ties with Ankara.

Deciding where you keep your money is an important decision, and you want to ensure you have the ideal bank account. If you're in the upper middle class, you may have certain expectations from your...

Intel’s (INTC) stock tumbled -12% in today’s trading session after the chip giant posted favorable Q4 results after market hours on Thursday but provided underwhelming guidance for the first quarter.

Investors often debate the merits of active versus index (passive) ETFs, but they can get the best of both worlds with the Avantis US Equity ETF ( NYSEARCA:AVUS ).  I’m bullish on this $5.8 billion ETF because I like its differentiated strategy, which combines some of the benefits of index investing, like excellent diversification and a low expense ratio, with active management in an effort to generate enhanced results. Additionally, it has proven itself as a winner with a strong three-year track record. What is the AVUS ETF’s Strategy? According to fund sponsor Avantis, which is part of American Century, AVUS “invests in a broad set of U.S. companies across all market capitalizations and is designed to increase expected returns by overweighting securities we believe to be trading at lower valuations and with higher profitability ratios.”  AVUS does this by placing more emphasis on stocks that its portfolio managers expect will generate higher returns, with a skew towards stocks with smaller market caps, higher profitability, and cheaper valuations. It then underweights or excludes stocks that the portfolio's management team expects to generate lower returns, including some stocks with larger market caps, lower profitability, and more expensive valuations.  AVUS “pursues the benefits associated with indexing (diversification, low turnover, transparency of exposures), but with the ability to add value by making investment decisions using information in current prices.” Essentially, AVUS takes the time-tested strategy of index investing and sprinkles in a bit of active management to try to boost returns. Supreme Diversification AVUS holds 2,273 stocks, offering investors supreme diversification. Furthermore, its top 10 holdings account for just 20.0% of the fund, so it isn’t overly concentrated in just a few large holdings like some funds are.  Because AVUS holds 2,273 stocks, it gives investors exposure to a much broader set of securities than the typical S&P 500 ( SPX ) funds, which own the 503 stocks in the S&P 500). Furthermore, its lower allocation to its top 10 holdings means that AVUS is more diversified and less concentrated than popular broad-market funds that invest in the S&P 500 like the Vanguard S&P 500 ETF ( NYSEARCA:VOO ) and the SPDR S&P 500 ETF Trust ( NYSEARCA:SPY ). These two prominent ETFs allocate 30.8% and 31.9% of assets towards their top 10 holdings, respectively.    AVUS is also diversified in terms of the sectors that it invests in. Information technology is the fund’s largest weighting, at 21%, followed by financials at 16% and consumer discretionary at 13%.  Below is an overview of the AVUS ETF’s top 10 holdings using TipRanks’ holdings tool.  As you can see, AVUS owns many of the mega-cap stocks that have propelled the stock market higher in recent years, like the "magnificent seven" tech stocks. However, because it goes underweight on many large-cap stocks and stocks with more expensive valuations, it has smaller weightings towards these stocks than broad-market index funds like VOO, SPY, and others. On the other hand, Lam Research ( NASDAQ:LRCX ) and Applied Materials ( NASDAQ:AMAT ) are good examples of stocks that AVUS overweights to its advantage.  Lam Research and Applied Materials are both companies that make equipment used in the semiconductor manufacturing process, and they have market capitalizations of $114.1 billion and $143.5 billion, respectively. Both rank within AVUS’ top 30 holdings, ahead of stocks with much larger market caps like UnitedHealth ( NYSE:UNH ) and Merck ( NYSE:MRK ), which feature market caps of $456.4 billion and $304.4 billion, respectively.   This selective weighting has worked out well for the fund, as Lam Research and Applied Materials are up 76.0% and 50.7% over the past year, while UnitedHealth and Merck are up 1.7% and 15.6%, respectively. For full transparency, these are just a few stocks that were cherrypicked, and there are likely examples where overweighting certain stocks didn't work out as well, but overall, this gives a general idea of what AVUS is trying to do to add to its returns. Lam Research and Applied Materials also boast strong Smart Scores of 10 and 8, respectively. The Smart Score is a proprietary quantitative stock scoring system created by TipRanks. It gives stocks a score from 1 to 10 based on eight market key factors. A score of 8 or above is equivalent to an Outperform rating. As you can see, AVUS offers many of the benefits of an index fund, but by targeting stocks that it believes can generate better returns, it has the ability to generate additional upside. Obviously, this strategy can backfire, but so far, it has generated solid results, as we’ll discuss below.  Results Show That the Strategy is Working So Far AVUS launched in September 2019, so it hasn’t been around long enough to compile a decades-long track record. But its results over the last few years are promising.  As of December 31, 2023, the fund generated a double-digit annualized return of 10.5% over a three-year period. This was slightly better than larger broad-market ETFs like VOO and SPY, which generated annualized returns of 10.0% and 9.9%, respectively, over the same time frame. A Cost-Effective Expense Ratio With an expense ratio of just 0.15%, AVUS is a cost-effective option for investors. An 0.15% expense ratio means an investor will pay just $15 in fees on a $10,000 investment annually. Assuming that the expense ratio remains 0.15% and the fund returns 5% per annum going forward, this investor initially allocating $10,000 into the fund would pay just $192 in fees over a 10-year time horizon. A 0.15% expense ratio is a bit more than many broad-market index funds charge (for example, the aforementioned VOO and SPY charge 0.03% and 0.09%, respectively), but it is still very cheap in the grand scheme of things. Many active and passively-managed funds charge much more than this, with lesser results. Is AVUS Stock a Buy, According to Analysts? Turning to Wall Street, AVUS earns a Moderate Buy consensus rating based on 1,546 Buys, 654 Holds, and 74 Sell ratings assigned in the past three months. The average AVUS stock price target of $90.57 implies 9.4% upside potential. The Best of Both Worlds With a well-diversified portfolio, cost-effective expense ratio, and strong three-year total returns, AVUS is the type of ETF that investors can use as a building block for their portfolios. It gives investors many of the benefits of investing in broad-market index funds but adds in a dash of active management, which can produce a bit of upside over time. This makes it an appealing and differentiated ETF that investors can build their portfolios around.   Disclosure

Soybean futures were down by another 10 to 14 cents across the front months, which left the weekly chart with the 11th red candle (-$1.50) over the past 12 weeks. Soymeal futures closed with more than 2% losses on Friday, leaving the front months at a weekly drop of $6....

Live cattle futures added another 72 cents to $1.25 to the upside across the front months on Friday. That pushed the Feb contract to a weekly $4.07 gain for the week and completed the 5th straight weekly green candle. Weekly cattle also held over their 18-wk moving average and the...

Friday’s hog market closed with 50 to 75 cent gains, which left the Feb contract up by $4.17 for the week to levels not seen since late Nov. USDA’s National Average Base Hog price increased by $1.64 to $56.27. The CME Lean Hog Index was $69.67 on 1/24, up by...

The front U.S. wheat futures faded into the weekend, but had held onto a weekly gain. Chicago futures ended the session with 11 ¼ to 12 cent losses, which left March at a net 7c gain to close over the $6 mark. KC wheat futures were down by 9 ½...

Friday’s 4 ½ to 5 ¾ cent losses left the board fractionally mixed for the week’s move. Preliminary OI data confirmed 5.8k fewer contracts were in play at the close yesterday, options however saw a surge of +22.3k contracts (+12.7k calls and +9.5k puts). The corn complex’s put/call ratio was...

After the old crop contracts extended their premium through the week, futures faded by triple digits to the old crop’s Friday losses of 50 points. That left the March contract with a weekly gain of 42 points, the Dec contract with a weekly gain of 40 points and the old...

Johnson & Johnson ( NYSE:JNJ ) stock's investment case is highly correlated with its underlying dividend prospects. As a healthcare giant with iconic brands like Band-Aid and Listerine, along with a diverse pharmaceutical and medical device portfolio, Johnson & Johnson has earned the trust of income-focused investors. With 61 consecutive years of dividend increases and another hike imminent, let's explore what is worth considering in the interim and why I am neutral on JNJ stock. Johnson & Johnson's Dividend is Utterly Recession-Proof The first point that I want to make clear is that Johnson and Johnson's dividend is utterly recession-proof. That's a bold claim, I know. In fact, it's important to address the skepticism that often surrounds the term "recession-proof." Numerous companies previously deemed recession-proof have cut their dividends, as illustrated by the case of AT&T ( NYSE:T ). Despite its surely recession-proof business model, as a provider of essential telecommunication services, the company was forced to cut its dividend in 2022 due to its unsustainable debt burden. This cautionary tale underscores the significance of being prudent and never taking any past trend for granted, especially when it comes to dividend growth. Nevertheless, and despite my efforts to scrutinize and challenge this claim, it is very hard to question the strength of Johnson & Johnson's dividend regardless of the underlying economic landscape. Johnson & Johnson boasts an incredibly diverse portfolio featuring a multitude of cutting-edge MedTech products. From general surgery and orthopedics to pharmaceuticals, vision care solutions, and a wide array of consumer health products, investing in Johnson & Johnson is more like buying a healthcare and consumer staples ETF rather than a single company. The company's healthcare products are critical for doctors to treat their patients. Simultaneously, the company's consumer staple products, like Band-Aid and Listerine, benefit from highly consistent sales due to their household staple nature. Therefore, Johnson & Johnson's cash flow profile tends to be extremely robust, ensuring its dividend remains well covered at all times. To support this argument with data, no three-year period in Johnson & Johnson's history has featured no revenue growth. The company has also continuously grown its adjusted earnings per share, maintaining a healthy payout ratio despite increasing the dividend year after year for more than six decades. Fiscal 2023 was no different, with Johnson & Johnson reporting adjusted earnings per share growth of 11.1% to $9.92, implying a payout ratio of just under 48% based on the $4.76 annualized dividend per share. Finally, it's worth mentioning that Johnson and Johnson is one of the only two publicly-traded companies, along with Microsoft ( NASDAQ:MSFT ), that have been granted a AAA credit rating by Standard & Poor's (as of August). The company is considered more creditworthy than the U.S. Government, whose credit rating has been downgraded to AA+. I believe this speaks volumes in terms of its overall financial soundness and, thus, ability to sufficiently cover its dividend along with other obligations/commitments. Another Dividend Hike is Coming -- What to Consider With Johnson & Johnson having already declared four $1.19 quarterly dividends, another dividend hike is likely coming. The company has increased its dividend every April or May as far back in time as one can see, so it's safe to assume that this year will be no different. While a dividend hike usually marks a reason to celebrate, particularly when it comes from seasoned dividend growers that income investors love, I believe that this is not the case with Johnson and Johnson and more. Specifically, despite the company's legendary dividend growth history, there is no doubt that dividend growth has undergone a clear deceleration trend, reaching a point of frustration. The company's 10-year compound annual growth rate seen over various periods paints a clear picture. Johnson & Johnson's 10-year dividend per share CAGR stood at: 14.8% in 2006 14.0% in 2008 13.4% in 2010 12.4% in 2012 9.7% in 2014 8.8% in 2016 7.0% in 2018 6.6% in 2021 6.4% in 2023 The trend is clear, with gradually smaller increases over time reducing the company's average dividend growth rate. Last year's dividend increase of just 5.3% was the weakest of them, pointing toward the fact that this trend won't be reversing anytime soon. Given that Johnson & Johnson's yield is not tremendous, standing at 2.9%, it's hard to be excited about the company's dividend prospects in the face of such a continuous deceleration. The deceleration appears rather puzzling, considering the ample coverage provided by earnings. Nevertheless, the sustained nature of this trend suggests a deliberate strategy by management. In my view, this will weigh negatively on JNJ stock investors despite the company's otherwise unparalleled qualities. Is JNJ Stock a Buy, According to Analysts? Regarding Wall Street’s view on the stock, Johnson & Johnson has a Moderate Buy consensus rating based on eight Buys and seven Holds assigned in the past three months. At $177.67, the  average JNJ stock forecast implies 11.4% upside potential. If you’re wondering which analyst you should follow if you want to buy and sell JNJ stock, the most profitable analyst covering the stock (on a one-year timeframe) is Danielle Antalffy of UBS, with an average return of 9.77% per rating and a 100% success rate. Click on the image below to learn more. The Takeaway Overall, while Johnson & Johnson's dividend growth track record displays remarkable resilience and underscores the company's recession-proof characteristics, the evident deceleration in dividend growth is a cause for concern. The company's diverse portfolio and robust cash flow position it as a reliable investment, but the slowing trend in dividend increases may impact investor sentiment. With another dividend hike on the horizon, I believe that investors should expect another below-average growth rate despite the company posting double-digit adjusted EPS growth in its Fiscal 2023 results. Disclosure

From Wall Street to Silicon Valley, wealthy donors have thrown tens of millions of dollars at Republican U.S. presidential candidate Nikki Haley in an effort to keep Donald Trump from returning to the White House.

A group opposed to affirmative action on Friday asked the Supreme Court to block the U.S. Military Academy at West Point from considering race as a factor in admissions decisions while a dispute over the practice proceeds in a lower court.